MABVAX THERAPEUTICS HLDGS INC
MBVX
MBVX was delisted on the 10th of July, 2018.
7 hedge funds and large institutions have $281K invested in MABVAX THERAPEUTICS HLDGS INC in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
31% less capital invested
Capital invested by funds: $405K → $281K (-$124K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$117K |
| 2 |
DRD
Dennis R. Delaney
|
+$38.1K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$972 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$201K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Millennium Management
New York
| $104K | +$117K | +10,229 | New |
|
|
BCM
2
Biomark Capital Management
Greenwich,
Connecticut
| $90K | – | – | – |
|
|
VKH
3
Virtu KCG Holdings
New York
| $53K | -$201K | -17,558 | -77% |
|
|
DRD
4
Dennis R. Delaney
| $34K | +$38.1K | +3,333 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| – | -$1K | -110 | Closed |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$1K | -45 | Closed |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$972 | +85 | +8,500% |
|
MBVX Hedge Fund Activity: Q4 2016 in Review
7 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in MABVAX THERAPEUTICS HLDGS INC (MBVX) for Q4 2016, worth a combined $281K — down 31% from $405K a quarter earlier.
Fund positioning in MBVX was balanced in Q4 2016: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $117K. The largest seller was Virtu KCG Holdings, cutting an estimated $201K.
- 7 institutional investors held MABVAX THERAPEUTICS HLDGS INC (MBVX) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $281K of MABVAX THERAPEUTICS HLDGS INC stock for Q4 2016, down 31% quarter-over-quarter.
- 2 funds opened new MABVAX THERAPEUTICS HLDGS INC positions in Q4 2016 and 2 closed out, a net change of 0 holders.
- The largest MABVAX THERAPEUTICS HLDGS INC buyer in Q4 2016 was Millennium Management, an estimated $117K added.
- The largest MABVAX THERAPEUTICS HLDGS INC seller in Q4 2016 was Virtu KCG Holdings, an estimated $201K sold.
Based on aggregated 13F filings for Q4 2016.